多西他赛联合塞替派治疗乳腺癌临床评价  

Docetaxel Combined with Thiotepa in the Treatment of Breast Cancer

作　　者：刘中强 王运伟 夏熙学 杨国鹏 张玉邦 LIU Zhongqiang;WANG Yunwei;XIA Xixue;YANG Guopeng;ZHANG Yubang(Cangxian County Hospital,Cangzhou,Hebei,China 061000)

机构地区：[1]河北省沧州市沧县医院,河北沧州061000

出　　处：《中国药业》2020年第14期91-94,共4页China Pharmaceuticals

基　　金：河北省医学科学研究重点课题[20171211]。

摘　　要：目的观察多西他赛联合塞替派治疗乳腺癌的近远期疗效及对患者缺氧诱导因子1(HIF-1)、血管内皮生长因子(VEGF)、血管内皮素(ET)水平的影响。方法选取医院2015年6月至2016年6月收治的行化学治疗(简称化疗)的乳腺癌患者86例,按奇偶数法分为观察组和对照组,各43例。两组患者均予基础治疗及静脉滴注多西他赛注射液,观察组患者加用塞替派注射液静脉滴注。结果观察组近期总有效率为88.37%,显著高于对照组的69.77%(P<0.05);与治疗前比较,两组患者治疗后的HIF-1,VEGF,ET水平均显著降低,且观察组均显著优于对照组(P<0.05);观察组患者的局部复发率、远端转移瘤、死亡率均显著低于对照组,无病生存率显著高于对照组(P<0.05);观察组与对照组不良反应发生率相当(23.26%比13.95%,χ^2=1.229,P=0.268>0.05)。结论多西他赛联合塞替派治疗乳腺癌,可提高患者的疾病缓解率和远期生存率,降低复发率和死亡率,同时降低血清恶性肿瘤相关生物学指标水平。Objective To observe the short and long-term efficacy of docetaxel combined with thiotepa in the treatment of breast cancer and its effect on the expression of hypoxia-inducible factor-1(HIF-1),vascular endothelial growth factor(VEGF)and vascular endothelin(ET).Methods A total of 86 patients with breast cancer treated by chemotherapy in the hospital from June 2015 to June2016 were selected and divided into the observation group and control group according the odd and even number table method,43 cases in each group.Both groups were given basic treatment and intravenous infusion of docetaxel injection,and the observation group were given intravenous infusion of thiotepa.Results The short-term total effective rate of the observation group was 88.37%,which was significantly higher than 69.77%of the control group(P<0.05).Compared with before treatment,the levels of HIF-1,VEGF and ET of the two groups were significantly reduced after treatment,and the improvements in the observation group were significantly better than those in the control group(P<0.05).The local recurrence rate,distal metastasis,and mortality of the observation group were significantly lower than the control group,and the disease-free survival rate was significantly higher than that of the control group(P<0.05).The incidence of adverse reactions in the observation group was comparable to that of the control group(23.26%vs.13.95%,χ^2=1.229,P=0.268>0.05).Conclusion Docetaxel combined with thiotepa in the treatment of breast cancer can improve the patient’s disease remission rate and long-term survival rate,reduce the recurrence rate and mortality,as well as reducing the level of serum malignant tumor-related biological indicators.

关 键 词：乳腺癌 化学治疗 多西他赛 塞替派 临床疗效 生物学指标 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]